Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · IEX Real-Time Price · USD
14.64
-0.08 (-0.51%)
Jul 22, 2024, 10:26 AM EDT - Market open
Tourmaline Bio Employees
Tourmaline Bio had 44 employees as of December 31, 2023.
Employees
44
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$748,591
Market Cap
377.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organogenesis Holdings | 862 |
| Revance Therapeutics | 597 |
| uniQure | 480 |
| Talkspace | 472 |
| Lyell Immunopharma | 224 |
| Sight Sciences | 214 |
| Vanda Pharmaceuticals | 203 |
| TScan Therapeutics | 154 |
TRML News
- 25 days ago - Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer - GlobeNewsWire
- 2 months ago - Tourmaline Bio to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial - GlobeNewsWire
- 2 months ago - Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Tourmaline Bio to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - GlobeNewsWire
- 6 months ago - Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire